Edwards Lifesciences Corporation

89.02+1.02+1.16%Vol 6.84M1Y Perf 22.64%
Apr 16th, 2021 16:00 DELAYED
BID88.25 ASK89.60
Open88.57 Previous Close88.00
Pre-Market- After-Market89.03
 - -  0.01 0.01%
Target Price
96.07 
Analyst Rating
Moderate Buy 1.79
Potential %
7.92 
Finscreener Ranking
★★★     50.88
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     52.18
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     73.76
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap55.37B 
Earnings Rating
Sell
Price Range Ratio 52W %
88.16 
Earnings Date
20th Apr 2021

Today's Price Range

87.6689.13

52W Range

66.2392.08

5 Year PE Ratio Range

31.3073.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.52%
1 Month
10.75%
3 Months
1.31%
6 Months
4.32%
1 Year
22.64%
3 Years
91.84%
5 Years
150.64%
10 Years
536.23%

TickerPriceChg.Chg.%
EW89.021.02001.16
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.20
3.50
0.13
0.15
59.00
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
75.40
21.30
23.70
26.40
15.28
RevenueValueIndustryS&P 500US Markets
3.26B
5.24
9.18
11.61
Earnings HistoryEstimateReportedSurprise %
Q04 20200.530.50-5.66
Q03 20200.450.5113.33
Q02 20200.150.34126.67
Q01 20200.430.5016.28
Q04 20190.490.490.00
Q03 20190.410.4714.63
Q02 20190.440.464.55
Q01 20190.410.447.32
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.47-6.00Negative
6/2021 QR0.51-1.92Negative
12/2021 FY2.130.00-
12/2022 FY2.46-1.60Negative
Next Report Date20th Apr 2021
Estimated EPS Next Report0.47
Estimates Count12
EPS Growth Next 5 Years %15.70
Volume Overview
Volume6.84M
Shares Outstanding622.04M
Trades Count30.67K
Dollar Volume255.88M
Avg. Volume2.63M
Avg. Weekly Volume2.05M
Avg. Monthly Volume2.53M
Avg. Quarterly Volume2.65M

Edwards Lifesciences Corporation (NYSE: EW) stock closed at 89.02 per share at the end of the most recent trading day (a 1.16% change compared to the prior day closing price) with a volume of 6.86M shares and market capitalization of 55.37B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14900 people. Edwards Lifesciences Corporation CEO is Michael A. Mussallem.

The one-year performance of Edwards Lifesciences Corporation stock is 22.64%, while year-to-date (YTD) performance is -2.42%. EW stock has a five-year performance of 150.64%. Its 52-week range is between 66.23 and 92.08, which gives EW stock a 52-week price range ratio of 88.16%

Edwards Lifesciences Corporation currently has a PE ratio of 65.20, a price-to-book (PB) ratio of 11.44, a price-to-sale (PS) ratio of 16.39, a price to cashflow ratio of 50.40, a PEG ratio of 2.32, a ROA of 11.52%, a ROC of 16.30% and a ROE of 18.12%. The company’s profit margin is 15.28%, its EBITDA margin is 23.70%, and its revenue ttm is $3.26 Billion , which makes it $5.24 revenue per share.

Of the last four earnings reports from Edwards Lifesciences Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.47 for the next earnings report. Edwards Lifesciences Corporation’s next earnings report date is 20th Apr 2021.

The consensus rating of Wall Street analysts for Edwards Lifesciences Corporation is Moderate Buy (1.79), with a target price of $96.07, which is +7.92% compared to the current price. The earnings rating for Edwards Lifesciences Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edwards Lifesciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edwards Lifesciences Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.12, ATR14 : 2.34, CCI20 : 137.84, Chaikin Money Flow : 0.15, MACD : 0.34, Money Flow Index : 87.33, ROC : 7.45, RSI : 53.58, STOCH (14,3) : 98.61, STOCH RSI : 1.00, UO : 59.66, Williams %R : -1.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edwards Lifesciences Corporation in the last 12-months were: Donald E. Bobo (Option Excercise at a value of $2 385 699), Donald E. Bobo (Sold 173 330 shares of value $15 337 791 ), Huimin Wang (Option Excercise at a value of $1 905 050), Huimin Wang (Sold 124 407 shares of value $10 761 691 ), Jean-Luc M. Lemercier (Option Excercise at a value of $1 022 570), Jean-Luc M. Lemercier (Sold 70 556 shares of value $6 554 133 ), Katie Szyman (Option Excercise at a value of $680 235), Katie Szyman (Sold 49 946 shares of value $4 290 261 ), Larry L. Wood (Option Excercise at a value of $2 879 587), Larry L. Wood (Sold 108 400 shares of value $9 460 284 ), Michael A. Mussallem (Option Excercise at a value of $14 952 827), Michael A. Mussallem (Sold 708 350 shares of value $59 743 592 ), Nicholas J. Valeriani (Option Excercise at a value of $469 304), Nicholas J. Valeriani (Sold 8 200 shares of value $698 752 ), Robert W.A. Sellers (Option Excercise at a value of $468 710), Robert W.A. Sellers (Sold 21 540 shares of value $1 779 160 ), Scott B. Ullem (Option Excercise at a value of $4 378 440), Scott B. Ullem (Sold 239 400 shares of value $18 728 867 ), Steven R. Loranger (Option Excercise at a value of $696 789)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (57.89 %)
11 (57.89 %)
12 (60.00 %)
Moderate Buy
1 (5.26 %)
1 (5.26 %)
1 (5.00 %)
Hold
7 (36.84 %)
7 (36.84 %)
7 (35.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.79
Moderate Buy
1.79
Moderate Buy
1.75

Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery.

CEO: Michael A. Mussallem

Telephone: +1 949 250-2500

Address: One Edwards Way, Irvine 92614, CA, US

Number of employees: 14 900

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

News

Stocktwits